Harry Magnani

731 total citations
9 papers, 457 citations indexed

About

Harry Magnani is a scholar working on Hematology, Surgery and Internal Medicine. According to data from OpenAlex, Harry Magnani has authored 9 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hematology, 5 papers in Surgery and 5 papers in Internal Medicine. Recurrent topics in Harry Magnani's work include Heparin-Induced Thrombocytopenia and Thrombosis (5 papers), Platelet Disorders and Treatments (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Harry Magnani is often cited by papers focused on Heparin-Induced Thrombocytopenia and Thrombosis (5 papers), Platelet Disorders and Treatments (5 papers) and Venous Thromboembolism Diagnosis and Management (5 papers). Harry Magnani collaborates with scholars based in Australia, United Kingdom and Netherlands. Harry Magnani's co-authors include Alexander Gallus, Edelgard Lindhoff‐Last, J. F. Cade, M.A. Barradas, J Necciari, Piérre Siè, B Boneu, A.M. Gabaig, Paresh Dandona and G Kieffer and has published in prestigious journals such as Thrombosis and Haemostasis, Journal of Thrombosis and Haemostasis and British Journal of Clinical Pharmacology.

In The Last Decade

Harry Magnani

9 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Harry Magnani Australia	7	325	313	187	160	140	9	457
J.F. Vitoux France	9	183 0.6×	219 0.7×	172 0.9×	111 0.7×	23 0.2×	19	339
Sebastian Schellong Germany	6	204 0.6×	158 0.5×	75 0.4×	116 0.7×	109 0.8×	13	281
A.T. Cohen United Kingdom	6	172 0.5×	391 1.2×	300 1.6×	80 0.5×	9 0.1×	9	432
R. Afzal United Kingdom	6	112 0.3×	133 0.4×	361 1.9×	24 0.1×	12 0.1×	7	405
Y. Whitney Cheung Netherlands	9	88 0.3×	280 0.9×	239 1.3×	84 0.5×	8 0.1×	13	344
Wolfgang Korte Switzerland	7	76 0.2×	66 0.2×	128 0.7×	73 0.5×	13 0.1×	8	286
R. Balzarotti Italy	7	203 0.6×	135 0.4×	135 0.7×	8 0.1×	20 0.1×	16	338
W Noszczyk Poland	8	146 0.4×	158 0.5×	106 0.6×	27 0.2×	4 0.0×	28	298
Michael Lincoff United States	8	208 0.6×	77 0.2×	272 1.5×	12 0.1×	12 0.1×	17	339
Erik Wellander Sweden	6	130 0.4×	178 0.6×	162 0.9×	36 0.2×	4 0.0×	7	302

Countries citing papers authored by Harry Magnani

Since Specialization

Citations

This map shows the geographic impact of Harry Magnani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry Magnani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry Magnani more than expected).

Fields of papers citing papers by Harry Magnani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry Magnani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry Magnani. The network helps show where Harry Magnani may publish in the future.

Co-authorship network of co-authors of Harry Magnani

This figure shows the co-authorship network connecting the top 25 collaborators of Harry Magnani. A scholar is included among the top collaborators of Harry Magnani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry Magnani. Harry Magnani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Magnani, Harry, et al.. (2022). Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. Thrombosis Journal. 20(1). 4–4. 7 indexed citations

2.

Magnani, Harry & Alexander Gallus. (2006). Heparin-induced thrombocytopenia (HIT): A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Journal of Thrombosis and Haemostasis. 95(6). 967–981. 4 indexed citations

3.

Gallus, Alexander & Harry Magnani. (2006). Heparin-induced thrombocytopenia (HIT). Thrombosis and Haemostasis. 95(6). 967–981. 79 indexed citations

4.

Magnani, Harry, et al.. (2004). Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thrombosis and Haemostasis. 93(1). 63–69. 60 indexed citations

5.

Chong, Beng H., J. F. Cade, Harry Magnani, et al.. (2001). Prospective Randomised Open-label Comparison of Danaparoid with Dextran 70 in the Treatment of Heparin-induced Thrombocytopaenia with Thrombosis. Thrombosis and Haemostasis. 86(11). 1170–1175. 106 indexed citations

6.

Boneu, B, J Necciari, R Cariou, et al.. (1995). Pharmacokinetics and Tolerance of the Natural Pentasaccharide (SR90107/ORG31540) with High Affinity to Antithrombin III in Man. Thrombosis and Haemostasis. 74(6). 1468–1473. 107 indexed citations

7.

Magnani, Harry. (1994). The Interpretation of Laboratory Data. Drug Information Journal. 28(2). 361–371. 1 indexed citations

8.

Gallus, Alexander, J. F. Cade, Paul Ockelford, et al.. (1993). Orgaran (Org 10172) or Heparin for Preventing Venous Thrombosis after Elective Surgery for Malignant Disease? A Double-Blind, Randomised, Multicentre Comparison. Thrombosis and Haemostasis. 70(4). 562–567. 45 indexed citations

9.

Mikhailidis, D.P., et al.. (1984). Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function.. British Journal of Clinical Pharmacology. 17(1). 43–48. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact